Copyright Reports & Markets. All rights reserved.

Global Milbemycin Oxime API Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Milbemycin Oxime API Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 98% Purity
    • 1.3.3 Purity Greater than 98%
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Milbemycin Oxime API Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Dog
    • 1.4.3 Cat
    • 1.4.4 Other
  • 1.5 Global Milbemycin Oxime API Market Size & Forecast
    • 1.5.1 Global Milbemycin Oxime API Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Milbemycin Oxime API Sales Quantity (2021-2032)
    • 1.5.3 Global Milbemycin Oxime API Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Livzon Pharmaceutical Group Inc
    • 2.1.1 Livzon Pharmaceutical Group Inc Details
    • 2.1.2 Livzon Pharmaceutical Group Inc Major Business
    • 2.1.3 Livzon Pharmaceutical Group Inc Milbemycin Oxime API Product and Services
    • 2.1.4 Livzon Pharmaceutical Group Inc Milbemycin Oxime API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Livzon Pharmaceutical Group Inc Recent Developments/Updates
  • 2.2 Zhejiang Hisun Pharmaceutical Co., Ltd
    • 2.2.1 Zhejiang Hisun Pharmaceutical Co., Ltd Details
    • 2.2.2 Zhejiang Hisun Pharmaceutical Co., Ltd Major Business
    • 2.2.3 Zhejiang Hisun Pharmaceutical Co., Ltd Milbemycin Oxime API Product and Services
    • 2.2.4 Zhejiang Hisun Pharmaceutical Co., Ltd Milbemycin Oxime API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Zhejiang Hisun Pharmaceutical Co., Ltd Recent Developments/Updates
  • 2.3 Hubei Honch Pharmaceutical Co.,Ltd
    • 2.3.1 Hubei Honch Pharmaceutical Co.,Ltd Details
    • 2.3.2 Hubei Honch Pharmaceutical Co.,Ltd Major Business
    • 2.3.3 Hubei Honch Pharmaceutical Co.,Ltd Milbemycin Oxime API Product and Services
    • 2.3.4 Hubei Honch Pharmaceutical Co.,Ltd Milbemycin Oxime API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Hubei Honch Pharmaceutical Co.,Ltd Recent Developments/Updates
  • 2.4 JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD
    • 2.4.1 JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD Details
    • 2.4.2 JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD Major Business
    • 2.4.3 JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD Milbemycin Oxime API Product and Services
    • 2.4.4 JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD Milbemycin Oxime API Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD Recent Developments/Updates

3 Competitive Environment: Milbemycin Oxime API by Manufacturer

  • 3.1 Global Milbemycin Oxime API Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Milbemycin Oxime API Revenue by Manufacturer (2021-2026)
  • 3.3 Global Milbemycin Oxime API Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Milbemycin Oxime API by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Milbemycin Oxime API Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Milbemycin Oxime API Manufacturer Market Share in 2025
  • 3.5 Milbemycin Oxime API Market: Overall Company Footprint Analysis
    • 3.5.1 Milbemycin Oxime API Market: Region Footprint
    • 3.5.2 Milbemycin Oxime API Market: Company Product Type Footprint
    • 3.5.3 Milbemycin Oxime API Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Milbemycin Oxime API Market Size by Region
    • 4.1.1 Global Milbemycin Oxime API Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Milbemycin Oxime API Consumption Value by Region (2021-2032)
    • 4.1.3 Global Milbemycin Oxime API Average Price by Region (2021-2032)
  • 4.2 North America Milbemycin Oxime API Consumption Value (2021-2032)
  • 4.3 Europe Milbemycin Oxime API Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Milbemycin Oxime API Consumption Value (2021-2032)
  • 4.5 South America Milbemycin Oxime API Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Milbemycin Oxime API Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Milbemycin Oxime API Sales Quantity by Type (2021-2032)
  • 5.2 Global Milbemycin Oxime API Consumption Value by Type (2021-2032)
  • 5.3 Global Milbemycin Oxime API Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Milbemycin Oxime API Sales Quantity by Application (2021-2032)
  • 6.2 Global Milbemycin Oxime API Consumption Value by Application (2021-2032)
  • 6.3 Global Milbemycin Oxime API Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Milbemycin Oxime API Sales Quantity by Type (2021-2032)
  • 7.2 North America Milbemycin Oxime API Sales Quantity by Application (2021-2032)
  • 7.3 North America Milbemycin Oxime API Market Size by Country
    • 7.3.1 North America Milbemycin Oxime API Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Milbemycin Oxime API Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Milbemycin Oxime API Sales Quantity by Type (2021-2032)
  • 8.2 Europe Milbemycin Oxime API Sales Quantity by Application (2021-2032)
  • 8.3 Europe Milbemycin Oxime API Market Size by Country
    • 8.3.1 Europe Milbemycin Oxime API Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Milbemycin Oxime API Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Milbemycin Oxime API Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Milbemycin Oxime API Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Milbemycin Oxime API Market Size by Region
    • 9.3.1 Asia-Pacific Milbemycin Oxime API Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Milbemycin Oxime API Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Milbemycin Oxime API Sales Quantity by Type (2021-2032)
  • 10.2 South America Milbemycin Oxime API Sales Quantity by Application (2021-2032)
  • 10.3 South America Milbemycin Oxime API Market Size by Country
    • 10.3.1 South America Milbemycin Oxime API Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Milbemycin Oxime API Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Milbemycin Oxime API Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Milbemycin Oxime API Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Milbemycin Oxime API Market Size by Country
    • 11.3.1 Middle East & Africa Milbemycin Oxime API Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Milbemycin Oxime API Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Milbemycin Oxime API Market Drivers
  • 12.2 Milbemycin Oxime API Market Restraints
  • 12.3 Milbemycin Oxime API Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Milbemycin Oxime API and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Milbemycin Oxime API
  • 13.3 Milbemycin Oxime API Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Milbemycin Oxime API Typical Distributors
  • 14.3 Milbemycin Oxime API Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Milbemycin Oxime API market size was valued at US$ 35.18 million in 2025 and is forecast to a readjusted size of US$ 54.18 million by 2032 with a CAGR of 6.3% during review period.
    Milbemime is a novel semi-synthetic macrolide anthelmintic, an oxime derivative of milbemime A3 and A4. The molecular weight of A3 oxime is 541.7, and that of A4 oxime is 555.7. In application, milbemime can be used alone or in combination with drugs such as nitenpyram, flufenoxuron, spinosad, and praziquantel to form compound preparations. These preparations are effective in controlling internal parasites such as canine heartworm, hookworm, roundworm, and whipworm, as well as external parasites such as folliculitis, lice, and fleas. Milbemime is an agonist of the γ-aminobutyric acid (GABA) neurotransmitter in nerve cells and can also bind to glutamate-gated chloride ion channels in the nerve and muscle cells of invertebrates. In both cases, it blocks the nerve signals of the parasites, ultimately leading to paralysis, loss of muscle contraction, cessation of feeding, and death of the parasite. In 2025, global sales of milbemycin oxime API reached approximately 2.5 tons, with an average price of about US$14,000 per kilogram. The industry's average gross profit margin exceeded 55%.
    Against the backdrop of continuous upgrading of the global veterinary drug industry and rapid development of the pet economy, the stable supply and technological capabilities of core active pharmaceutical ingredients (APIs) are becoming crucial factors determining industry competitiveness. As a key active ingredient widely used in parasite control, Milbemycin API is gradually evolving from a single-function ingredient into a fundamental substance supporting the modern veterinary drug system, with its market value and strategic importance continuously increasing.
    Milbemycin is a macrolide compound primarily used to kill internal and external parasites, and is widely used in deworming preparations for companion animals such as dogs and cats. Its mechanism of action is well-defined, its spectrum of action is broad, and its safety profile is high, making it one of the core components in current pet deworming drug systems. As the source of efficacy in formulations, the quality stability, purity control, and batch consistency of Milbemycin API directly affect the safety and market acceptance of downstream veterinary drug products, highlighting its fundamental role in the entire industry chain.
    From a market structure perspective, global demand for Milbemycin-related formulations is highly correlated with the growth in the pet population and the increasing standardization of pet healthcare. With the increasing adoption of companion animals in households, growing awareness of medical care, and the growing popularity of regular deworming, the penetration rate of milbemime-based deworming products continues to rise in both mature and emerging markets. This trend provides stable and long-term demand support for the milbemime API market, making it one of the most promising segments in the veterinary drug API sector.
    From the supply side, the production of milbemime API has certain technical and process barriers. Its synthetic route is complex, and process control requirements are high, placing high demands on the stability of fermentation or chemical synthesis processes, impurity control capabilities, and quality systems. This gives API companies with mature process accumulation and sound quality management systems a greater competitive advantage in the market. As global veterinary drug regulations become stricter, milbemime API suppliers that meet international standards and have continuous supply capabilities will find it easier to enter the supply chains of mainstream veterinary drug companies.
    In terms of supply chain collaboration, milbemime API is gradually forming closer cooperative relationships with downstream formulation companies. Pharmaceutical formulation companies are increasingly demanding higher standards for the stability, compliance, and traceability of raw material sources. This has transformed active pharmaceutical ingredients (APIs) from price-driven products into crucial foundations for cooperation driven by quality and supply capacity. This shift is propelling the milbemime API market from fragmented competition to a quality-oriented approach and long-term partnerships.
    Regional markets show stable demand for milbemime formulations in mature markets like Europe, the US, and Japan, with high requirements for API quality and compliance. Meanwhile, emerging markets in Asia and Latin America are experiencing more significant demand growth, driven by increasing pet numbers and the standardization of the veterinary drug market. As a major global production base for veterinary drug APIs, China is gradually enhancing its technological capabilities and international market participation in the milbemime API sector, possessing the potential to extend into higher segments of the global supply chain.
    Looking ahead, the milbemime API market will focus more on high-quality, compliant, and large-scale supply capabilities. With the continuous improvement of veterinary drug regulations, competition among API companies regarding process stability, quality consistency, and international registration support capabilities will intensify further. Meanwhile, the development of companion animal medicine towards long-term and preventative medication will also bring continuous and stable demand growth for milbemoxime raw materials.
    This report is a detailed and comprehensive analysis for global Milbemycin Oxime API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Milbemycin Oxime API market size and forecasts, in consumption value ($ Million), sales quantity (KG), and average selling prices (US$/KG), 2021-2032
    Global Milbemycin Oxime API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (KG), and average selling prices (US$/KG), 2021-2032
    Global Milbemycin Oxime API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (KG), and average selling prices (US$/KG), 2021-2032
    Global Milbemycin Oxime API market shares of main players, shipments in revenue ($ Million), sales quantity (KG), and ASP (US$/KG), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Milbemycin Oxime API
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Milbemycin Oxime API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Livzon Pharmaceutical Group Inc, Zhejiang Hisun Pharmaceutical Co., Ltd, Hubei Honch Pharmaceutical Co.,Ltd, JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Milbemycin Oxime API market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    98% Purity
    Purity Greater than 98%
    Market segment by Application
    Dog
    Cat
    Other
    Major players covered
    Livzon Pharmaceutical Group Inc
    Zhejiang Hisun Pharmaceutical Co., Ltd
    Hubei Honch Pharmaceutical Co.,Ltd
    JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Milbemycin Oxime API product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Milbemycin Oxime API, with price, sales quantity, revenue, and global market share of Milbemycin Oxime API from 2021 to 2026.
    Chapter 3, the Milbemycin Oxime API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Milbemycin Oxime API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Milbemycin Oxime API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Milbemycin Oxime API.
    Chapter 14 and 15, to describe Milbemycin Oxime API sales channel, distributors, customers, research findings and conclusion.

    Buy now